EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan

Kenji Hiraizumi, Chikara Honda, Ayu Watanabe, Takafumi Nakao, Shuichi Midorikawa, Hiromi Abe, Nobuki Matsui, Tsunehisa Yamamoto, Takahiko Sakamoto

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02515-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Kenji Hiraizumi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Medical Affairs, Ono Pharmaceutical Co., Ltd., 1-8-2 Kyutaromachi, Chuo-ku, Osaka, 541-8564, Japan. Hauptthemen laut MEDLINE: Nivolumab, Product Surveillance, Postmarketing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ono Pharmaceutical, Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nivolumab has been approved for treating ≥ 10 cancer types. However, there is limited information on the incidence of rare, but potentially serious, treatment-related adverse events (TRAEs), as well as notable TRAEs in patients with certain medical disorders or older patients in Japan.

Methods

We performed pooled analyses of data from published post-marketing surveillance in Japan of nivolumab monotherapy for patients with malignant melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancer, and gastric cancer to determine the frequencies of 20 categories of TRAEs of special interest overall and in patient groups with higher perceived safety risks (history of autoimmune disease, interstitial lung disease, tuberculosis, or hepatitis B/C; patients vaccinated during nivolumab treatment; and older patients [≥ 75 years]).

Results

The overall population comprised 7421 patients treated with nivolumab. TRAEs were reported in 49.1% of patients, with grade ≥ 3 TRAEs in 16.7%. Endocrine disorders (14.4%), hepatobiliary disorders (10.9%), and interstitial lung disease (7.0%) were the three most common categories (any grade). The incidences of rare TRAEs with high risk of becoming serious, which occurred in < 1% of patients, were consistent with those in previous reports. The frequencies of TRAEs were not markedly increased in the specified patient groups relative to the overall population.

Conclusion

To our knowledge, this is the largest study examining the safety of nivolumab-treated patients in real-world clinical practice including rare but potentially serious TRAEs. We found no new signals in the safety of nivolumab among the patient groups relative to the overall population, and no additional safety measures are required in these groups.

Trial registration

UMIN000048892 (overall analysis), JapicCTI-163272 (melanoma), Japic-163271 (non-small cell lung cancer), JapicCTI-184071 (head and neck cancer), JapicCTI-184070 (gastric cancer), and JapicCTI-184069 (renal cell cancer).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabProduct Surveillance, PostmarketingHumansJapanAgedMaleFemaleStomach NeoplasmsNeoplasmsMiddle AgedMelanomaCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellHead and Neck NeoplasmsAdultKidney NeoplasmsAntineoplastic Agents, ImmunologicalAged, 80 and overIncidence

Stichwörter der Autor:innen

NivolumabPost-marketing surveillanceReal-world clinical practiceSafetyTreatment-related adverse events

Substanzen

NivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Oncology Medical Affairs, Ono Pharmaceutical Co., Ltd., 1-8-2 Kyutaromachi, Chuo-ku, Osaka, 541-8564, Japan.
  • PV Data Strategy, Pharmacovigilance Department, Ono Pharmaceutical Co., Ltd., 2-1-5 Dosho-machi, Chuo-ku, Osaka, 541-8526, Japan.
  • Safety Management Pharmacovigilance Department, Ono Pharmaceutical Co., Ltd., 2-1-5 Dosho-machi, Chuo-ku, Osaka, 541-8526, Japan.
  • Biometrics and Data Sciences, R&D Department, Bristol-Myers Squibb K.K., Otemachi One Tower, 1-2-1 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan.
  • Oncology Medical, Bristol-Myers Squibb K.K., Otemachi One Tower, 1-2-1 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan.
  • Patient Safety Japan, Bristol-Myers Squibb K.K., Otemachi One Tower, 1-2-1 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan.

Förderung

  • Ono Pharmaceutical
  • Bristol Myers Squibb

Zitieren

APA

Hiraizumi, K., Honda, C., Watanabe, A., Nakao, T., Midorikawa, S., Abe, H., Matsui, N., Yamamoto, T., & Sakamoto, T. (2024). Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02515-1

Vancouver

Hiraizumi K, Honda C, Watanabe A, Nakao T, Midorikawa S, Abe H, et al. Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02515-1

BibTeX
@article{Hiraizumi2024,
  author = {Hiraizumi, Kenji and Honda, Chikara and Watanabe, Ayu and Nakao, Takafumi and Midorikawa, Shuichi and Abe, Hiromi and Matsui, Nobuki and Yamamoto, Tsunehisa and Sakamoto, Takahiko},
  title = {Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02515-1}
}
Kostenlos starten →